These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 21288345)
21. Molecular markers of antifolate resistance in Plasmodium falciparum isolates from Luanda, Angola. Gama BE; Pereira-Carvalho GA; Lutucuta Kosi FJ; Almeida de Oliveira NK; Fortes F; Rosenthal PJ; do Rosário VE; Daniel-Ribeiro CT; de Fátima Ferreira-da-Cruz M Malar J; 2011 Aug; 10():248. PubMed ID: 21864379 [TBL] [Abstract][Full Text] [Related]
22. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Baraka V; Ishengoma DS; Fransis F; Minja DT; Madebe RA; Ngatunga D; Van Geertruyden JP Malar J; 2015 Nov; 14():439. PubMed ID: 26542942 [TBL] [Abstract][Full Text] [Related]
23. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575 [TBL] [Abstract][Full Text] [Related]
24. The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana. Dosoo DK; Bailey JA; Asante KP; Oppong FB; Niaré K; Opoku-Mensah J; Owusu-Agyei S; Greenwood B; Chandramohan D PLoS One; 2022; 17(8):e0271489. PubMed ID: 35939419 [TBL] [Abstract][Full Text] [Related]
25. High prevalence of sulphadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo. Koukouikila-Koussounda F; Bakoua D; Fesser A; Nkombo M; Vouvoungui C; Ntoumi F Infect Genet Evol; 2015 Jul; 33():32-6. PubMed ID: 25934142 [TBL] [Abstract][Full Text] [Related]
26. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran. Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131 [TBL] [Abstract][Full Text] [Related]
27. Molecular Markers of Sulfadoxine-Pyrimethamine Resistance in Samples from Children with Uncomplicated Plasmodium falciparum at Three Sites in Angola in 2019. Rosillo SR; Dimbu PR; Cândido ALM; Oh JM; Ferreira CM; Nieto Andrade B; Labuda S; Horth R; Kelley J; Morais JFM; Fortes F; Martins JF; Talundzic E; Pluciński MM Antimicrob Agents Chemother; 2023 Apr; 67(4):e0160122. PubMed ID: 36916920 [TBL] [Abstract][Full Text] [Related]
28. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Moussiliou A; De Tove YS; Doritchamou J; Luty AJ; Massougbodji A; Alifrangis M; Deloron P; Ndam NT Malar J; 2013 Jun; 12():195. PubMed ID: 23758883 [TBL] [Abstract][Full Text] [Related]
29. Increasing prevalence of a novel triple-mutant dihydropteroate synthase genotype in Plasmodium falciparum in western Kenya. Lucchi NW; Okoth SA; Komino F; Onyona P; Goldman IF; Ljolje D; Shi YP; Barnwell JW; Udhayakumar V; Kariuki S Antimicrob Agents Chemother; 2015 Jul; 59(7):3995-4002. PubMed ID: 25896703 [TBL] [Abstract][Full Text] [Related]
30. Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. Artimovich E; Schneider K; Taylor TE; Kublin JG; Dzinjalamala FK; Escalante AA; Plowe CV; Laufer MK; Takala-Harrison S J Infect Dis; 2015 Sep; 212(5):694-701. PubMed ID: 25672905 [TBL] [Abstract][Full Text] [Related]
31. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Enosse S; Magnussen P; Abacassamo F; Gómez-Olivé X; Rønn AM; Thompson R; Alifrangis M Malar J; 2008 Jul; 7():115. PubMed ID: 18590577 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran. Zakeri S; Afsharpad M; Raeisi A; Djadid ND Malar J; 2007 Nov; 6():148. PubMed ID: 17999755 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. Tahita MC; Tinto H; Erhart A; Kazienga A; Fitzhenry R; VanOvermeir C; Rosanas-Urgell A; Ouedraogo JB; Guiguemde RT; Van Geertruyden JP; D'Alessandro U PLoS One; 2015; 10(9):e0137440. PubMed ID: 26368675 [TBL] [Abstract][Full Text] [Related]
35. Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Bertin G; Briand V; Bonaventure D; Carrieu A; Massougbodji A; Cot M; Deloron P Malar J; 2011 Jul; 10():196. PubMed ID: 21767415 [TBL] [Abstract][Full Text] [Related]
36. Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso. Bohissou FET; Sondo P; Inoue J; Rouamba T; Kaboré B; Nassa GJW; Kambou AES; Traoré TE; Asua V; Borrmann S; Tinto H; Held J Sci Rep; 2024 Oct; 14(1):24224. PubMed ID: 39414909 [TBL] [Abstract][Full Text] [Related]
37. Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes. Sitali L; Mwenda MC; Miller JM; Bridges DJ; Hawela MB; Hamainza B; Mudenda-Chilufya M; Chizema-Kawesha E; Daniels RF; Eisele TP; Nerland AH; Chipeta J; Lindtjorn B Acta Trop; 2020 Dec; 212():105704. PubMed ID: 33002448 [TBL] [Abstract][Full Text] [Related]
38. Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation. Cohen O; Guemas E; Menard S; Tsague Kenfack M; Talom Ngassa C; Iriart X; Bidzogo Lebobo M; Ondobo Ekae C; Eboumbou C; Tiyou Kenmeni C; Berry A J Antimicrob Chemother; 2023 Mar; 78(3):665-668. PubMed ID: 36611259 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy. Warsame M; Hassan AH; Hassan AM; Arale AM; Jibril AM; Mohamud SA; Barrette A; Muse AY; Yusuf FE; Nada RA; Amran JG Trop Med Int Health; 2017 Apr; 22(4):415-422. PubMed ID: 28151566 [TBL] [Abstract][Full Text] [Related]
40. Polymorphism in drug resistance genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium falciparum in some states of India. Sharma D; Lather M; Mallick PK; Adak T; Dang AS; Valecha N; Singh OP Parasit Vectors; 2015 Sep; 8():471. PubMed ID: 26381498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]